arrow
E

Ezra E.W. Cohen

University of California System
H指数:85
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma
2024-10-220
OAAI
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
2024-03-0112
OAAI
A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer

功能性鉴定平台揭示了癌症患者中频繁的自发新抗原特异性T细胞反应

2024-02-282
OA
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040) : Subgroup analysis by pattern of disease recurrence

帕博利珠单抗与甲氨蝶呤,多西他赛或西妥昔单抗在复发或转移性头颈部鳞状细胞癌中的比较 (KEYNOTE-040): 疾病复发模式的亚组分析

2023-12-014
OAAI
Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors (vol 24, pg 1345, 2023)

新抗原特异性干细胞记忆样CD4 T细胞介导MHC II类阴性实体瘤的CD8 T细胞依赖性免疫疗法 (第24卷,1345页,2023页)

2023-07-180
OAAI
Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors

新抗原特异性干细胞记忆样CD4 T细胞介导MHC ⅱ 类阴性实体瘤的CD8 T细胞依赖性免疫治疗

2023-07-0331
OAAI
Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)
2023-04-140
PRE
Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
2023-04-141
PRE
Eganelisib, a First-in-Class PI3Kg Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

Eganelisib,一类PI3Kg抑制剂,用于晚期实体瘤患者: 1/1b期MARIO-1试验的结果

2023-03-3126
OA